NCT02418156已完成不适用
A Post Market Observational Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 38
- 主要终点
- Device-Related Adverse Events
研究概览
简要总结
To gather information on the use of CorMatrix ECM for Vascular Repair in the reconstruction of the femoral artery.
详细描述
OBJECTIVE The objective of the study is to actively gather additional information on the use of CorMatrix ECM for vascular repair in the reconstruction of the femoral artery. The CorMatrix ECM for Vascular Repair may be used for patch closure of vessels, as a pledget, or for suture line buttressing when repairing peripheral vessels.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be undergoing femoral arterial reconstruction with patch angioplasty closure
- •Surgeon intends to use CorMatrix ECM per FDA cleared Indications for Use
- •Subject possesses ability to provide informed consent
- •Subject expresses understanding and willingness to fulfill all expected requirements of protocol
排除标准
- •Known sensitivity to porcine material
结局指标
主要结局
Device-Related Adverse Events
时间窗: Up to 12 months follow-up
Proportion of patients experiencing device related adverse events.
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
CorMatrix ECM for Carotid Repair Following Endarterectomy RegistryCarotid StenosisNCT01569594Aziyo Biologics, Inc.230
已完成
不适用
Coroflex ISAR NEO "All Comers" Post Market Clinical Follow-up (PMCF)Coronary Artery DiseaseNCT03809715B. Braun Melsungen AG3,520
撤回
不适用
ACHIEVE GRX RegistryPeripheral Vascular DiseasesRenal Artery DiseaseCarotid Artery DiseasesPeripheral Arterial DiseaseNCT04513613Corindus Inc.
Unknown
不适用
Post Market Clinical Follow-up Study for Arthroplasty Shoulder System of FX Solutions at the Long TermShoulder DiseaseShoulder FracturesShoulder Arthroplasty for Revision of Previous TreatmentNCT05284357FX Solutions416
撤回
不适用
Miromatrix Biological Mesh for Ventral Hernia RepairVentral HerniaNCT02408458Miromatrix Medical Inc.
